Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KITE-753 vs Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma
NCT07479797Phase 3Active, not recruiting
- Sponsor
- Kite Pharma
- Start
- May 2026
- Primary completion
- May 2031
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 9
01
Overview
A Phase 3 trial of KITE-753 in Diffuse Large B-Cell Lymphoma (DLBCL), sponsored by Kite Pharma. Started May 2026; status: active, not recruiting.
02
Drugs
KITE-753
03
Conditions
Diffuse Large B-Cell Lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07479797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07479797.